About the PTAB Life Sciences Report:  Each month we will report on developments at the PTAB involving life sciences patents.

McKesson Corp. v. My Health, Inc.

PTAB Petition:  IPR2017-00312; filed November 29, 2016.

Patent at Issue:  U.S. Patent No. 6,612,985 ("Method and system for monitoring and treating a patient," issued September 2, 2003) claims a method for tracking compliance with treatment guidelines as well as a system for tracking compliance in treating patients comprising an assessment processing system.

Petitioners McKesson Corp., McKesson Technologies Inc., InTouch Technologies, Inc., and Medical Depot, Inc. are challenging the '985 patent on nine grounds as being anticipated under 35 U.S.C. § 102(b) (grounds 1, 6, and 8) or as obvious under 35 U.S.C. § 103(a) (grounds 2-5, 7, and 9).  View the petition here.

Related Matters:  According to the petition, the '985 patent is currently the subject of the following litigations:  My Health, Inc. v. McKesson Technologies Inc., 2:16-cv-00881, Eastern District of Texas (Marshall Division); My Health, Inc. v. InTouch Technologies, Inc., 2:16-cv-00536, Eastern District of Texas (Marshall Division); My Health, Inc. v. DeVilbiss Healthcare, LLC, 2:16-cv-00544, Eastern District of Texas (Marshall Division); My Health, Inc. v. MyNetDiary, Inc., 2:16-cv-00866, Eastern District of Texas (Marshall Division); My Health, Inc. v. ALR Technologies, Inc., 2:16-cv-00535, Eastern District of Texas (Marshall Division); Human Design Medical, LLC v. My Health, Inc., 1:16-cv-00767, District of Delaware; and Fit4D, Inc. v. My Health, Inc., 1:16-cv-01076, District of Delaware.  
The '985 patent has been the subject of four prior IPR petitions, all of which were terminated prior to a final written decision:  IPR2013-00320 (Cardiocom, LLC, filed 05/31/2013; granted 11/19/2013; terminated 02/20/2014); IPR2014-00435 (Click4Care, Inc., filed 02/14/2014; terminated 06/06/2014); IPR2015-00102 (Biotronik, Inc., filed 10/21/2014; granted 04/16/2015; terminated 07/28/2015); and IPR2015-01218 (Robert Bosch Healthcare Systems, Inc., filed 05/18/2015; terminated 07/28/2015; denied 05/23/2016), and IPR2016-01111 (Dr. Reddy's Laboratories, Ltd., filed 05/31/2016; pending).

MonoSol Rx, LLC v. ICOS Corp.

PTAB Petition:  IPR2017-00412; filed December 6, 2016.

Patent at Issue:  U.S. Patent No. 6,943,166 ("Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction [sic]," issued September 13, 2005) claims a method of treating sexual dysfunction in a patient in need thereof comprising orally administering inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase type 5.

Petitioner MonoSol Rx, LLC is challenging the '166 patent on three grounds as obvious under 35 U.S.C. § 103(a).  View the petition here.

Related Matters:  According to the petition, the '166 patent is currently the subject of the following litigations (all in the Eastern District of Virgina):  Eli Lilly v. Cipla USA, Inc., et al., 16-cv-1208, Eli Lilly v. Aurobindo Pharma Ltd., et al., 16-cv-1121, Eli Lilly v. Alembic Pharma., Ltd., et al., 16-cv-1120, Eli Lilly v. Mylan Pharma., Inc., 16-cv-1122, Eli Lilly v. Actavis Laboratories UT, Inc., 16-cv-1119, Eli Lilly v. Sun Pharmaceuticals Industries, Ltd., et al., 16-cv-518, Eli Lilly v. Teva Pharmaceuticals, USA, Inc., 16-cv-519, Eli Lilly v. Zydus Pharma. (USA), Inc., 16-cv-520; Eli Lilly v. Sun Pharma. Industries, 16-cv-1168, Eli Lilly v. Teva Pharma. USA, Inc., 16-cv-1169, and Eli Lilly v. Zydus Pharma. (USA) Inc., 16-cv-1170.  Also, the '166 patent was/is the subject of Inter Partes Review IPR2016-00678 (IntelGenX Corp.; filed 02/26/2016; denied 09/01/2016), and IPR2017-00323 (Mylan Pharmaceuticals; filed 11/22/2016; pending).

Edwards Lifesciences Corp. v. Boston Scientific Corp. and Boston Scientific Scimed, Inc.

PTAB Petition:  IPR2017-00444; filed December 7, 2016.

Patent at Issue:  U.S. Patent No. 6,915,560 ("Apparatus for contracting, loading or crimping self-expanding and balloon expandable stent devices," issued July 12, 2005) claims a stent crimper apparatus for manipulating a medical device comprising at least three coupled movable blades.

Petitioner Edwards Lifesciences Corp is challenging the '560 patent on two grounds as obvious under 35 U.S.C. § 103(a).  View the petition here.

Related Matters:  According to the petition, the '560 patent is subject of a litigation captioned Boston Scientific Corp. and Boston Scientific Scimed, Inc. v. Edwards Lifesciences Corp., Civil Action No. 8:16-cv-0730 (C.D. Cal.).

Alembic Pharmaceuticals Ltd. v. UCB Pharma GmbH
Amerigen Pharmaceuticals Ltd. v. UCB Pharma GmbH
Torrent Pharmaceuticals, Ltd. v. UCB Pharma GmbH

PTAB Petition:  IPR2016-01596; filed August 22, 2016.

PTAB Petition:  IPR2016-01665; filed August 22, 2016.

PTAB Petition:  IPR2016-01636; filed August 18, 2016.

PTAB Trial Instituted Document filed December 7, 2016.

Patent at Issue:  U.S. Patent No. 6,858,650 ("Stable salts of novel derivatives of 3,3-diphenylpropylamines," issued February 22, 2005) claims derivatives of 3,3-diphenylpropylamines and salt forms.

Petitioners Alembic Pharmaceuticals (IPR2016-01596), Amerigen Pharmaceuticals (IPR2016-01665), and Torrent Pharmaceuticals, Ltd. (IPR2016-01636) are challenging the '650 patent on three grounds as obviousness under 35 U.S.C. § 103(a).  All Petitioners seek joinder with IPR2016-00510 (Mylan Pharmaceuticals Inc. and Mylan Laboratories Ltd.; filed 2/2/2016; instituted 7/20/2016) through Motions for Joinder under 35 U.S.C. § 315(c), 37 C.F.R. §§ 42.22 and 42.122(b).  View the petitions here (IPR2016-01596); here (IPR2016-01665); and here (IPR2016-01636).  Administrative Patent Judges Kristina M. Kalan, Robert A. Pollock, and Michelle N. Ankenbrand (author) issued a decision instituting inter partes review of whether claims 1–5 and 21–24 of the '650 patent as obvious under 35 U.S.C. § 103 over the combination of Postlind, Bundgaard publications, Detrol Label, and Berge; and claims 1–5 and 21–24 of the '650 patent as obvious under 35 U.S.C. § 103 over the combination of Brynne, Bundgaard publications, and Johansson.  The Judges also ordered that Case IPR2016-01596, Case IPR2016-01665, and Case IPR2016-01636 are joined with IPR2016-00510 and administratively terminated under 37 C.F.R. § 42.72, and all further filings in the joined proceedings shall be made in Case IPR2016-00510.  View the decisions here (IPR2016-01596); here (IPR2016-01665); and here (IPR2016-01636).

Related Matters:  According to the petition, the '650 patent is involved in litigation in the District of Delaware, captioned Pfizer, Inc. and UCB Pharma GmbH v. Mylan Pharmaceuticals, Inc., No. 1:15-cv-00079-GMS; the Northern District of West Virginia, captioned Pfizer Inc. and UCB Pharma GmbH v. Mylan Pharmaceuticals Inc., No. 1:15-cv-00013-IMK; and in the District of Delaware, captioned Pfizer, Inc. and UCB Pharma GmbH v. Sandoz, Inc., et al., No. 1:13-cv-01110-GMS.

Medtronic PLC v. Neurovision Medical Products, Inc.

PTAB Petition:  IPR2017-00456; filed December 8, 2016.

Patent at Issue:  U.S. Patent No. 8,634,894 ("Electrode for prolonged monitoring of laryngeal electromyography," issued January 21, 2014) claims a device for use in monitoring electrical signals during laryngeal electromyography.

Petitioners Medtronic PLC, Medtronic Xomed, Inc., and Medtronic, Inc. are challenging the '894 patent on six grounds as being obvious under 35 U.S.C. § 103(a).  View the petition here.

Related Matters:  According to the petition, the '894 Patent is the subject of a litigation captioned Neurovision Medical Products, Inc. v. Medtronic Public Limited Company et al., No. 2:16-CV-00127 (E.D. Tx.).  Also, the '894 patent was and is involved in IPR2015-00502 (Petitioner, NuVasive, Inc.; filed 12/24/2014; terminated through settlement 07/29/2015); IPR2016-01405 (Petitioners, Medtronic PLC, Medtronic Xomed, Inc., and Medtronic, Inc; filed 07/11/2016; instituted 12/29/2016); IPR2016-01406 (Petitioners, Medtronic PLC, Medtronic Xomed, Inc., and Medtronic, Inc; filed 07/11/2016; instituted 12/29/2016).  Petitioner has filed a Motion for Joinder under 35 U.S.C. § 315(c) and 37 C.F.R. §§ 42.22–42.122(b), to join the instant proceeding with IPR2016-01405 and IPR2016-1406.

Mylan Pharmaceuticals Inc. v Allergan, Inc.

PTAB Petition:  IPR2016-01127; filed June 3, 2016.

PTAB Trial Instituted Document filed December 8, 2016.

Patent at Issue:  U.S. Patent No. 8,685,930 ("Methods of providing therapeutic effects using cyclosporin components," issued April 1, 2014) claims a topical ophthalmic emulsion comprising cyclosporin A for treating an eye with keratoconjuctivitis sicca.

Petitioner Mylan Pharmaceuticals Inc. is challenging the '930 patent on three grounds as being anticipated under 35 U.S.C. § 102(b) (ground 1) or as obvious under 35 U.S.C. § 103(a) (grounds 2 and 3).  View the petition here.  Administrative Patent Judges Sheridan K. Snedden (author), Tina E. Hulse, and Christopher G. Paulraj issued a decision instituting inter partes review of whether claims 1−36 of the '930 patent are anticipated under 35 U.S.C. § 102 by Ding '979; claims 1−36 of the '930 patent are obvious under 35 U.S.C. § 103(a) over the combination of Ding '979 and Sall; and claims 11, 23, and 35 of the '930 patent are obvious under 35 U.S.C. § 103(a) over the combination of Ding '979, Sall, and Acheampong.

Related Matters:  According to the petition, the '930 patent is involved in litigations captioned Allergan, Inc. v. Teva Pharmaceuticals USA, Inc., et al., No. 2:15-cv-01455 (E.D. Tex.); Allergan, Inc., v. Innopharma, Inc. and Pfizer, Inc., No. 2:15-cv-1504 (E.D. Tex.); and Allergan, Inc. v. Famy Care, Ltd., No. 2:16-cv-0401 (E.D. Tex.).  Also, the '048 patent (see below) was the subject of IPR2015-01283 (Petitioners Apotex Corp. and Apotex Inc.; filed 06/04/2015; terminated through settlement 12/16/2015).  Petitioner concurrently filed inter partes review petitions to related patents in Case IPR2016-01128 (U.S. Patent No. 8,629,111 B2); Case IPR2016-01129 (U.S. Patent No. 8,642,556 B2); Case IPR2016-01130 (U.S. Patent No. 8,633,162 B2); Case IPR2016-01131 (U.S. Patent No. 8,648,048 B2); and Case IPR2016-01132 (U.S. Patent No. 9,248,191 B2).

Mylan Pharmaceuticals Inc. v Allergan, Inc.

PTAB Petition:  IPR2016-01128; filed June 3, 2016.

PTAB Trial Instituted Document filed December 8, 2016.

Patent at Issue:  U.S. Patent No. 8,629,111 ("Methods of providing therapeutic effects using cyclosporin components," issued February 11, 2014) claims a topical ophthalmic emulsion comprising cyclosporin A.

Petitioner Mylan Pharmaceuticals Inc. is challenging the '111 patent on three grounds as being anticipated under 35 U.S.C. § 102(b) (ground 1) or as obvious under 35 U.S.C. § 103(a) (grounds 2 and 3).  View the petition here.  Administrative Patent Judges Sheridan K. Snedden, Tina E. Hulse, and Christopher G. Paulraj (author) issued a decision instituting inter partes review of whether claims 1−27 are anticipated under 35 U.S.C. § 102(b) by Ding '979; claims 1−27 are obvious under 35 U.S.C. § 103(a) over the combination of Ding '979 and Sall; and claims 11 and 16 as obvious under 35 U.S.C. § 103(a) over the combination of Ding '979, Sall, and Acheampong.

Related Matters:  According to the petition, the '048 patent (see below) is involved in litigations captioned Allergan, Inc. v. Teva Pharmaceuticals USA, Inc., et al., No. 2:15-cv-01455 (E.D. Tex.); Allergan, Inc., v. Innopharma, Inc. and Pfizer, Inc., No. 2:15-cv-1504 (E.D. Tex.); and Allergan, Inc. v. Famy Care, Ltd., No. 2:16-cv-0401 (E.D. Tex.).  Also, the '048 patent was the subject of IPR2015-01282 (Petitioners Apotex Corp. and Apotex Inc.; filed 06/04/2015; terminated through settlement 12/16/2015).  Petitioner concurrently filed inter partes review petitions to related patents IPR2016-01127 (U.S. Patent No. 8,685,930 B2); Case IPR2016-01129 (U.S. Patent No. 8,642,556 B2); Case IPR2016-01130 (U.S. Patent No. 8,633,162 B2); Case IPR2016-01131 (U.S. Patent No. 8,648,048 B2); and Case IPR2016-01132 (U.S. Patent No. 9,248,191 B2).

Mylan Pharmaceuticals Inc. v Allergan, Inc.

PTAB Petition:  IPR2016-01129; filed June 3, 2016.

PTAB Trial Instituted Document filed December 8, 2016.

Patent at Issue:  U.S. Patent No. 8,642,556 ("Methods of providing therapeutic effects using cyclosporin components," issued February 4, 2014) claims a topical ophthalmic emulsion for treating a human eye comprising comprising cyclosporin A.

Petitioner Mylan Pharmaceuticals Inc. is challenging the '556 patent on five grounds as being anticipated under 35 U.S.C. § 102(b) (ground 1) or obviousness under 35 U.S.C. § 103(a) (grounds 2 through 5).  View the petition here.  Administrative Patent Judges Sheridan K. Snedden, Tina E. Hulse, and Christopher G. Paulraj (author) issued a decision instituting inter partes review of whether claims 1–20 are anticipated under 35 U.S.C. § 102(b) by Ding '979; claims 1–20 are obvious under 35 U.S.C. § 103(a) over Ding '979 and Sall; claims 14 and 19 are obvious under 35 U.S.C. § 103(a) over Ding '979, Sall, and Glonek; claims 11, 18, and 20 are obvious under 35 U.S.C. § 103(a) over Ding '979, Sall, and Acheampong; and claim 19 is obvious under 35 U.S.C. § 103(a) over Ding '979, Sall, Glonek, and Acheampong.

Related Matters:  According to the petition, the '556 patent is involved in litigations captioned Allergan, Inc. v. Teva Pharmaceuticals USA, Inc., et al., No. 2:15-cv-01455 (E.D. Tex.); Allergan, Inc., v. Innopharma, Inc. and Pfizer, Inc., No. 2:15-cv-1504 (E.D. Tex.); and Allergan, Inc. v. Famy Care, Ltd., No. 2:16-cv-0401 (E.D. Tex.).  Also, the '048 patent (see below) was the subject of IPR2015-01286 (Petitioners Apotex Corp. and Apotex Inc.; filed 06/04/2015; terminated through settlement 12/16/2015).  Petitioner concurrently filed inter partes review petitions to related patents IPR2016-01127 (U.S. Patent No. 8,685,930 B2); Case IPR2016-01128 (U.S. Patent No. 8,629,111 B2); Case IPR2016-01130 (U.S. Patent No. 8,633,162 B2); IPR2016-01131 (U.S. Patent No. 8,648,048 B2); and Case IPR2016-01132 (U.S. Patent No. 9,248,191 B2).

Mylan Pharmaceuticals Inc. v Allergan, Inc.

PTAB Petition:  IPR2016-01130; filed June 3, 2016.

PTAB Trial Instituted Document filed December 8, 2016.

Patent at Issue:  U.S. Patent No. 8,633,162 ("Methods of providing therapeutic effects using cyclosporin components," issued February 4, 2014) claims a method of treating dry eye disease comprising topically administering an emulsion comprising cyclosporin A.

Petitioner Mylan Pharmaceuticals Inc. is challenging the '162 patent on three grounds of being obvious under 35 U.S.C. § 103(a).  View the petition here.  Administrative Patent Judges Sheridan K. Snedden, Tina E. Hulse (author), and Christopher G. Paulraj issued a decision instituting inter partes review of whether claims 1–10, 12–14, 16–20, and 22–24 are obvious over Ding '979 and Sall; claims 11 and 21 are obvious over Ding '979, Sall, and Acheampong; and claim 15 is obvious over Ding '979, Sall, and Glonek.

Related Matters:  According to the petition, the '162 patent is involved in litigations captioned Allergan, Inc. v. Teva Pharmaceuticals USA, Inc., et al., No. 2:15-cv-01455 (E.D. Tex.); Allergan, Inc., v. Innopharma, Inc. and Pfizer, Inc., No. 2:15-cv-1504 (E.D. Tex.); and Allergan, Inc. v. Famy Care, Ltd., No. 2:16-cv-0401 (E.D. Tex.).  Also, the '048 patent (see below) was the subject of IPR2015-01278 (Petitioners Apotex Corp. and Apotex Inc.; filed 06/04/2015; terminated through settlement 12/16/2015).  Petitioner concurrently filed inter partes review petitions to related patents IPR2016-01127 (U.S. Patent No. 8,685,930 B2); Case IPR2016-01128 (U.S. Patent No. 8,629,111 B2); Case IPR2016-01129 (U.S. Patent No. 8,642,556 B2); IPR2016-01131 (U.S. Patent No. 8,648,048 B2); and Case IPR2016-01132 (U.S. Patent No. 9,248,191 B2).

Mylan Pharmaceuticals Inc. v Allergan, Inc.

PTAB Petition:  IPR2016-01131; filed June 3, 2016.

PTAB Trial Instituted Document filed December 8, 2016.

Patent at Issue:  U.S. Patent No. 8,648,048 ("Methods of providing therapeutic effects using cyclosporin components," issued February 11, 2014) claims method of increasing tear production in the eye of a human by topically administering an emulsion comprising cyclosporin A.

Petitioner Mylan Pharmaceuticals Inc. is challenging the '048 patent on three grounds as being obvious under 35 U.S.C. § 103(a).  View the petition here.  Administrative Patent Judges Sheridan K. Snedden (author), Tina E. Hulse, and Christopher G. Paulraj issued a decision instituting inter partes review of whether claims 1–10, 12–14, 16–20, 22, and 23 are obvious over Ding '979 and Sall; claims 11 and 21 are obvious over Ding '979, Sall, and Acheampong; and claim 15 is obvious over Ding '979, Sall, Acheampong, and Glonek.

Related Matters:  According to the petition, the '048 patent is involved in litigations captioned Allergan, Inc. v. Teva Pharmaceuticals USA, Inc., et al., No. 2:15-cv-01455 (E.D. Tex.); Allergan, Inc., v. Innopharma, Inc. and Pfizer, Inc., No. 2:15-cv-1504 (E.D. Tex.); and Allergan, Inc. v. Famy Care, Ltd., No. 2:16-cv-0401 (E.D. Tex.).  Also, the '048 patent was the subject of IPR2015-01284 (Petitioners Apotex Corp. and Apotex Inc.; filed 06/04/2015; terminated through settlement 12/16/2015).  Petitioner concurrently filed inter partes review petitions to related patents IPR2016-01127 (U.S. Patent No. 8,685,930 B2); Case IPR2016-01128 (U.S. Patent No. 8,629,111 B2); Case IPR2016-01129 (U.S. Patent No. 8,642,556 B2); Case IPR2016-01130 (U.S. Patent No. 8,633,162 B2); and Case IPR2016-01132 (U.S. Patent No. 9,248,191 B2).